IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 278 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $133 | -35.4% | 29,200 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $206 | +35.5% | 29,200 | +17.3% | 0.00% | 0.0% |
| Q1 2023 | $152 | -4.4% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $159 | -99.9% | 24,900 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $239,000 | -13.1% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $275,000 | -33.7% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $415,000 | -12.6% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $475,000 | -22.6% | 24,900 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $614,000 | -5.2% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $648,000 | -17.8% | 24,900 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $788,000 | -31.8% | 24,900 | 0.0% | 0.00% | -42.9% |
| Q4 2020 | $1,155,000 | +71.1% | 24,900 | +21.5% | 0.01% | +40.0% |
| Q3 2020 | $675,000 | -40.1% | 20,500 | -50.0% | 0.01% | 0.0% |
| Q2 2020 | $1,126,000 | – | 41,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |